Lipid Nanoparticles: A Comprehensive Assessment of Liver Enzymes and Immunopathology Markers in Nonhuman Primates
Leveraging Nonclinical Safety Evaluation Findings to Expedite Next-Generation Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) Development for Metabolic Disorders and Beyond
Intravenous Sampling and Administration Using InstechVascular Access Buttons in Rodents: Pathology Findings Related to Indwelling Vascular Catheter
Intra-Cerebroventricular (ICV) Route in Mice for Administration of Gene Therapy Products
Immunomodulatory Approaches in Preclinical Gene Therapy Studies
An Examination of the Effects of Body Temperature on QT Interval in Non-Naïve Telemetered Göttingen Minipigs®
GLP-1 RA: Overcoming Known Pharmacological Effects
GLP-1 RA: Rapid Clinical Phase I Study Execution
Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
Laval, Québec, November 21, 2024—Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i, an ultra-long-acting injectable, fully biased GLP-1 receptor agonist.
In September, Metsera reported positive topline results from the clinical trial conducted at Altasciences’ facility, in which MET-097i demonstrated a 7.5% reduction in body weight from baseline at day 36 (one week after the final dose) and a 380-hour half-life. This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i.
In addition to clinical conduct, Altasciences supported Metsera with its Acceleration Platform, including nonclinical, bioanalysis, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altasciences has completed nonclinical work for MET-233i, an ultra-long-acting injectable amylin analog, as well as MET-002, an oral GLP-1 receptor agonist peptide, which has proven instrumental in allowing Metsera to begin clinical trials for both programs this year.
"Congratulations to Metsera on reaching this significant milestone in the development of MET-097i," said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. "Metsera is a highly valued partner of Altasciences, and we are proud to have contributed to this program aimed at helping individuals struggling with obesity-related illnesses."
Obesity impacts millions of people worldwide and is a driver of serious health risks, including type 2 diabetes, heart disease, and certain cancers. Innovative treatments, like MET-097i, could offer potential new treatment options for those affected by this complex condition.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to nonclinical and clinical pharmacology studies, including drug product formulation and manufacturing services, through its Acceleration Platform for early-phase drug development. For over 30 years, Altasciences has been partnering with sponsors to help support faster, more informed, and more confident early drug development decisions. By aligning scientific, regulatory, and operational functions within a single coordinated framework, the Acceleration Platform enables parallel execution across development activities to help reduce traditional handoffs and delays between phases. Altasciences’ integrated, full-service solutions include nonclinical safety testing, clinical pharmacology and proof-of-concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors reach critical development milestones sooner and get better drugs to the people who need them, faster.
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com